Overview of ACTIV trial-specific lessons learned.
| Autor: | Draghia-Akli R; The Janssen Pharmaceutical Companies of Johnson & Johnson, Spring House, PA, USA., Read SW; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA., Hughes EA; Teva Pharmaceuticals, Parsippany, NJ, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of clinical and translational science [J Clin Transl Sci] 2024 Oct 15; Vol. 8 (1), pp. e149. Date of Electronic Publication: 2024 Oct 15 (Print Publication: 2024). |
| DOI: | 10.1017/cts.2023.698 |
| Abstrakt: | Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) was an extraordinary example of a public-private partnership (PPP) that brought together over thirty organizations and hundreds of individuals to address one of the most pressing global health needs in recent decades. In particular, ACTIV provided a key avenue for testing numerous therapeutics for their potential benefit in treating the SARS-CoV-2 virus or the resulting symptoms of acute COVID-19 infection. Given the speed and scale at which ACTIV designed and implemented master protocols across global networks that it was simultaneously working to create, the PPP can provide valuable lessons for best practices and avoiding pitfalls the next time the world is faced with a global pandemic of a novel pathogen. This report provides a general overview of the ACTIV partnership to set the stage and context for the subsequent articles in this issue that will relay these lessons learned. Competing Interests: None. (© The Author(s) 2024.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|